E7389 (Eribulin) is a synthetic analog of halichondrin B (HB), which is a natural marine product extracted from marine sponge Halichondria okadai, and had shown in preclinical studies to have highly potent anti-cancer activity in vitro and in vivo. Eribulin has demonstrated activity in refractory breast cancer. Eribulin was evaluated in a single-arm Phase II trial in female patients with refractory breast cancer, ECOG performance status of 0–1, measurable disease, and neuropathy Grade 2. Patients had received a median of 4 prior chemotherapy regimens. The overall response rate was 15%, which is high, considering the population of resistant patients treated. 1/3 of patients did not progress in 6 months. The most common drug related toxicities were neutropenia (low white blood cell count), fever, fatigue, alopecia (hair loss), nausea, and anemia.
CORT is conducting a Phase III study of Eribulin versus the treatment of physician’s choice’ in patients with locally recurrent or metastatic breast cancer. Patients are eligible if they have been previously treated with at least two and a maximum of five prior chemotherapy regimens, Including an anthracycline and a taxane.
For more information on these studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: Breast Cancer, E7389, Eribulin, Eribulin Mesylate, metastatic breast cancer, refractory breast cancer
